Propanc Biopharma
PPCB
2 hedge funds and large institutions have $191K invested in Propanc Biopharma in 2025 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.04% more ownership
Funds ownership: 0% → 0.04% (+0.04%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MG
Marex Group
London,
|
+$182K |
| 2 |
VF
Virtu Financial
New York
|
+$108K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MG
1
Marex Group
London,
| $120K | +$182K | +2,817 | New |
|
|
VF
2
Virtu Financial
New York
| $71K | +$108K | +1,667 | New |
|
3
Morgan Stanley
New York
| $2 | – | – | – |
|
PPCB Hedge Fund Activity: Q3 2025 in Review
2 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Propanc Biopharma (PPCB) for Q3 2025, worth a combined $191K.
Buyers outnumbered sellers: 2 funds opened new PPCB positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Marex Group, opening a new position worth an estimated $182K.
- 2 institutional investors held Propanc Biopharma (PPCB) as of Q3 2025, up from 0 in Q2 2025.
- Funds reported $191K of Propanc Biopharma stock for Q3 2025.
- 2 funds opened new Propanc Biopharma positions in Q3 2025 and 0 closed out, a net change of +2 holders.
- The largest Propanc Biopharma buyer in Q3 2025 was Marex Group, an estimated $182K added.
Based on aggregated 13F filings for Q3 2025.